Monday, April 11, 2016

19 April 2016: Impact of regulatory structure on quality of medicines in India

Dinesh Thakur
Sciformix Corporation

Quality of medicines dispensed in the Indian market has been an area of concern for quite some time now. Prosecution of Ranbaxy Laboratories, once India's largest pharmaceutical company in the US bought issues of data integrity and product quality to light. Since that time, foreign regulators like the US FDA and the EMA have increased their focus on Indian manufacturers to make sure that the medicines made in India and sold in those markets are of high quality. Unfortunately, precious little has changed in India.

One of the key challenges to creating public awareness about this issue is the lack of think-tanks and research organizations which focus on this issue. This talk outlines the efforts undertaken to approach the Supreme Court challenging the constitutionality of the legal framework that forms the basis of drug regulation with an intent to develop a better understanding among policy analysts.

Date: April 19, 2016
Time: 04:30 P.M.

Conference Hall, Ground Floor, R&T Building
National Institute of Public Finance and Policy,
18/2 Satsang Vihar Marg, Special Institutional Area,
New Delhi-110067(INDIA)


View Larger Map

Those who are interested may please confirm your participation at

No comments:

Post a Comment